# Impact of changes in US Medicaid reimbursement for long-acting reversible contraceptives in the immediate postpartum period

Sarah Walker<sup>1</sup>, Simone Crespi<sup>2</sup>, Emilia Kourmaeva<sup>1</sup>, Gursimer Jeet<sup>1</sup>, Greta Lozano-Ortega<sup>1</sup> <sup>1</sup>Broadstreet HEOR, Vancouver, B.C., Canada; <sup>2</sup>Organon & Co, Jersey City, New Jersey

## **Background & Objective**

- Medicaid reimbursement for long-acting reversible contraceptives (LARC) provided in the immediate post-partum period (IPP) during the same hospital visit as birth has historically been part of the diagnosis-related group (DRG) fee Figure 1. Components reimbursed under carve-out by state<sup>21</sup> Both Device Insertion Non
- To rectify the financial disincentive providers faced, some states implemented policies to reimburse hospitals for IPP-LARC in addition to the DRG fee (Medicaid carve-out)
- This study aimed to characterize outcomes associated with these Medicaid policies for the provision of IPP-LARC



Figure 2. Year of carve-out policy implementation by state<sup>21</sup>



# Study Design & Methods

- A systematic literature review was conducted on November 2022 using Medline, EMBASE, and CINAHL
- All studies were screened by title/abstract and full text by two independent reviewers and included if they were a U.S. observational study of women or girls receiving IPP-LARC under a Medicaid carve-out
- Two independent reviewers extracted outcomes of interest including IPP-LARC use rates, pregnancy or birth rate, and authors' conclusions on the success of the policy



N=6 studies discussed associated **co-interventions** 

### **Results, continued**

- not reach statistical significance
- 2015/2016 to 2016/2017 in Missouri

Figure 3. Comparing IPP-LARC uptake and birth/pregnancy outcomes from the pre-to post-carve-out period



Mixed results included studies where authors found both positive and no significant effect from the Medicaid carveout across outcomes or demographics measured, as well as studies which found no statistically significant effect

- carve-out periods (Figure 3)
- with p<0.05) and short interval births (n=1 with p<0.05)
- **IPP-LARC**.



Studies with mixed results were those where authors found both positive and negative effect from the Medicaid carve-out across outcomes or demographics measured, as well as studies which found a positive but no statistically significant effect. Superscript numbers indicate study references

**ISPOR 2024** 

### **IPP-LARC** Uptake

Studies which calculated the statistical significance of differences in IPP-LARC uptake prevs. post carve-out (n=9) found that LARC uptake increased significantly after the carve-out implementation (p<0.05), except for two studies in Iowa in which the numerical increases did

Eighteen studies reported a descriptive change in IPP-LARC uptake in the post-carve-out period compared to the pre-policy period (Figure 3), ranging from a 0.16 percentage point increase between 2016 to 2017 in Wisconsin, to an 11.1 percentage point increase from

Of studies investigating pregnancy or birth outcomes (n=6), 2 reported overall positive impact of the carve-out, 3 reported mixed results, and 1 study didn't provide a relevant comparison (Figure 4). Two studies compared pregnancy or birth outcomes between the pre and post

• The carve-out policy change was found to lower risk of short-interval pregnancies (n=3

In South Carolina, improvements in birth outcomes reached statistical significance only in adolescents (p<0.01), but not adults (p=0.14), and in Ohio, although there was a decrease in the number of patients with repeat pregnancies among those receiving IPP-LARC, the mean interpregnancy interval in these patients was shorter than those who chose not to receive

# **Additional Results**

Table 1. Factors affecting the success of carve-out programs, as identified by study authors

State Factors important to carve- out success, or limitations	OH1	TN <sup>2</sup>	WI <sup>3</sup>	GA, IA, MD, NY, RI <sup>4</sup>	DE⁵	IA, LA 18	SC⁵	SC <sup>7</sup>	SC <sup>8</sup>	SC <sup>9</sup>	SC <sup>10</sup>	sc⁼	<b>GA</b> <sup>12</sup>	PA <sup>™</sup>
Receiving reimbursement from Medicaid (e.g. ability to reform hospital billing practices)		>	>	>					>					
Having provider champion(s) at a hospital, regional, or state level		>		>	>	>			>					
Raising awareness and providing training in IPP- LARC use for physicians and admin			<		>	>	>		>					
Additional co-interventions (laws, other policies etc.)	<	<			~	~			>					
Ability to stock and supply devices	>					>	>							
Inequality in IPP-LARC use and the impact of the carve- out (e.g. the impact of hospital size or location, concerns about contraceptive coercion of minorities or young patients)	>	>	>	>	>		>	>	>	>		>	>	~
Impact of carve-out on patients not covered under Medicaid	~	~		~	~								~	

Abbreviations: IPP-LARC, immediate postpartum long-acting reversible contraception; LARC, long-acting reversible contraceptives

Check marks indicate that the factor was discussed in the study. Superscript numbers indicate study references.

- A key determinant of carve-out success at the hospital level was support from policy champions (e.g. to update billing systems) or cointerventions (e.g. additional state policies supporting LARC use, or local campaigns aimed at increasing hospital staff training, raising awareness, or advocating for a global increase in LARC access) (Table 1)
- Many studies (n=15) provided evidence or raised concerns of the demographics of patients able to access IPP-LARC through the carveout, specifically the potential for contraceptive coercion of racial minorities and women living in poverty

### Conclusions

- Medicaid's IPP-LARC reimbursement carve-outs were found to be effective at increasing LARC usage and improving birth outcomes, such reducing short interval pregnancies, reduction in short interval births, preterm birth, and low birth weight births, as well as an increase in the length of the interpregnancy interval.
- States can improve carve-out implementation by providing cointerventions and promoting hospital policy champions.

#### Disclosures & Funding

This study was funded by Organon.

• SW, EK, GJ and GLO are employees of Broadstreet HEOR which received funding from Organon for this work. SC is an employee of Organon.

#### References

 1. AR Brant et al. Obstet Gynecol 2021;138(5):732-737.
 13. AKQ Hess et al. Obstet Gynecol 2022;139(SUPPL

 2.MM Lacy et al. AJOG 2020;222(4S):S910 e911-S910
 1):8S-9S

3.RD Kramer et al. WHI 2021;31(4):317-323 4.MW Steenland et al. JAMA Netw Open 2022a:5(10):e2237918 5.ML Caudillo et al. JMCH 2022;26(8):1657-1666 6.MW Steenland et al. Health Aff 2021;40(2):334-342 7.A Liberty et al. AJOC 2020;222(4s):S886 e881-S886 18. EM Okoroh AJOC 2018;218(6):590 e591-590 e 597

e889 
 8.A Mattison-Faye University of South Carolina 2019
 20. J Bakk AJOG 2021;138(5):732-737

 9.MW Steenland et al. 2022b;176(3):296-303
 21. ACOG 2023; https://www.acog.org
 10.AH Crockett et al. Contraception 2017;95(1):71-76 11. MW Steenland et al. JAMA 2019;322(1) 12.M Smith et al. Matern Child Health J. 2021;25(9):1361-1368

14.J Xing et al. WA State Dept. of Social and Health Services 2019 15.SK Koch Contraception 2022;113:57-61

16.AK Addante *Obstet Gynecol* 2020;135(SUPPL 1):110S 17.EM De La Garza *Obstet Gynecol* 2017;129(SUPPL







19.RB Paul Obstet Gynecol 2018;131(SUPPL 1):80S-81S

21. ACOG 2023; https://www.acog.org/programs/long acting-reversible-contraception-larc/activitiesinitiatives/medicaid-reimbursement-for-postpartum